Concepedia
Statistics
Publications
13
Citations
696
H-Index
12
Active since
1997
Affiliations
AstraZeneca (United Kingdom)(Current)
Queen Elizabeth Hospital
Paul Scorer is an author at AstraZeneca (United Kingdom) specializing in oncology, medicine, and molecular oncology.
Publications per year
1997–2021
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer
M. Ratcliffe, Alan Sharpe, Anita Midha et al. · Clinical Cancer Research · 2017 · 304 citations
Medicine, Oncology, Cancer Immunology +16
Phospho‐STAT5 and phospho‐Akt expression in chronic myeloproliferative neoplasms
Lizz Grimwade, Lisa Happerfield, Colin Tristram et al. · British Journal of Haematology · 2009 · 76 citations · Full text
Medicine, Cell Biology, Hematology +14
Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay.
Marietta Scott, Michel E. Vandenberghe, Paul Scorer et al. · Journal of Clinical Oncology · 2021 · 53 citations
Medicine, Oncology, Breast Oncology +14
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
M Zając, Marietta Scott, M. Ratcliffe et al. · Diagnostic Pathology · 2019 · 47 citations · Full text
Medicine, Oncology, Pathology +17
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
Paul Scorer, Marietta Scott, Nicola Lawson et al. · Diagnostic Pathology · 2018 · 37 citations · Full text
Medicine, Cancer Biology, Oncology +17
1–5 of 13